This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nieschlag, E. Articles by Wu, F. C. W. Search for Related Content PubMed PubMed Citation Articles by Nieschlag, E. Articles by Wu, F. C. W.

Investigation, Treatment, and Monitoring of Late-Onset Hypogonadism in Males: ISA, ISSAM, and EAU Recommendations

R. SWERDLOFF

H. M. BEHRE

L. J. GOOREN

C. SCHULMAN

C. WANG

W. WEIDNER

From the ^* Institute of Reproductive Medicine, University of Münster, Germany; the Division of Endocrinology and the General Clinical Research Center, Harbor-UCLA Medical Center, and Los Angeles BioMedical Research Institute, Torrance, California; the Andrology Unit, Department of Urology, Martin-Luther-University, Halle, Germany; the Department of Endocrinology/Andrology, Free University Hospital, Amsterdam, The Netherlands; the ^|| Department of Endocrinology, Academish Ziekenhuis, Gent, Belgium; the ^¶ Centre Hospitalier Universitaire, Sart-Tilman, Liège, Belgium; ^# Faculty of Life Sciences, Bar-Ilan University, Israel; the ^** Division of Geriatric Medicine, St Louis University, St Louis, Missouri; the Department of Urology, University Clinic of Brussels, Erasme Hospital, Belgium; the Department of Urology, Justus-Liebig-University, Giessen, Germany; and the ^|||| Central Manchester Healthcare NHS Trust, Manchester, United Kingdom.

The recommendations described below were prepared for the International Society of Andrology (ISA) and the International Society for the Study of the Aging Male (ISSAM), following a panel discussion with active participation from the audience sponsored by the ISA at the 4th ISSAM Congress in Prague in February 2004. The ISA Member Societies were requested to comment on the draft guidelines. Representatives of the European Association of Urology (EAU) participated in the development of the final draft of this document. This document is not intended to provide evidence for each recommendation, as a review of pertinent studies has recently been comprehensively summarized in the Clinical Research Directions on "Testosterone and Aging" by the Institute of Medicine (Washington, DC: 2004). The recommendations will be subject to revision as larger-scale and longer-term data become available.

In order to reach a large audience, these recommendations are published in the International Journal of Andrology, the Journal of Andrology, The Aging Male, and in European Urology.

Recommendation 1

Definition of late-onset hypogonadism (LOH): A clinical and biochemical syndrome associated with advancing age and characterized by typical symptoms and a deficiency in serum testosterone levels. It may result in significant detriment in the quality of life and adversely affect the function of multiple organ systems.

Recommendation 2

LOH is a syndrome characterized primarily by:

1. The easily recognized features of diminished sexual desire (libido) and erectile quality and frequency, particularly nocturnal erections,
   
2. Changes in mood with concomitant decreases in intellectual activity, cognitive functions, spatial orientation ability, fatigue, depressed mood, and irritability,
   
3. Sleep disturbances,
   
4. Decrease in lean body mass with associated diminution in muscle volume and strength,
   
5. Increase in visceral fat,
   
6. Decrease in body hair and skin alterations,
   
7. Decreased bone mineral density resulting in osteopenia, osteoporosis, and increased risk of bone fractures.
   

Recommendation 3

In patients at risk for or suspected of hypogonadism in general and LOH in particular, a thorough physical and biochemical work-up is mandatory and especially, the following biochemical investigations should be done:

1. A serum sample for total testosterone determination and sex hormone binding globulin (SHBG) should be obtained between 0700 and 1100 hours. The most widely accepted parameters to establish the presence of hypogonadism are the measurement of total testosterone and free testosterone calculated from measured total testosterone and SHBG or measured by a reliable free testosterone dialysis method.
   
2. There are no generally accepted lower limits of normal and it is unclear whether geographically different thresholds depend on ethnic differences or on the physicians' perception. There is, however, general agreement that total testosterone levels above 12 nmol/L (346 ng/dL) or free testosterone levels above 250 pmol/L (72 pg/mL) do not require substitution. Similarly, based on the data of younger men, there is consensus that serum total testosterone levels below 8 nmol/L (231 ng/dL) or free testosterone below 180 pmol/L (52 pg/mL) require substitution. Since symptoms of testosterone deficiency become manifest between 12 and 8 nmol/L, trials of treatment can be considered in those in whom alternative causes of these symptoms have been excluded. (Since there are variations in the reagents and normal ranges among laboratories, the cutoff values given for serum testosterone and free testosterone may have to be adjusted depending on the reference values given by each laboratory).
   
3. Salivary testosterone has been shown to be a reliable substitute for free testosterone measurements, but cannot be recommended at this time since the methodology has not been standardized and adult male ranges are not available in most hospital or reference laboratories.
   
4. If testosterone levels are below or at the lower limit of the accepted normal adult male values, it is recommended to perform a second determination together with assessment of serum luteinizing hormone and prolactin.
   

Recommendation 4

1. It is recognized that significant alterations in other endocrine systems occur in association with aging, but the significance of these changes is not well understood. In general terms, determinations of thyroid hormones, cortisol, DHEA, DHEA-S, melatonin, growth hormone, and insulin like growth factor-I are not indicated in the uncomplicated evaluation of late-onset hypogonadism. If endocrine disorders are suspected, assessment of these and other hormones may be warranted.
   
2. Diabetes mellitus type 2 is a frequent disorder of aging men. It is unclear at the present time what effect testosterone has on blood sugar and insulin sensitivity; thus, until positive effects of testosterone on blood sugar control are definitively demonstrated, diabetes should be evaluated and treated before or simultaneously with testosterone substitution.
   
3. In aging men with the major complaint of erectile dysfunction, lipids and the cardiovascular status should be assessed.
   

Recommendation 5

A clear indication based on a clinical picture together with biochemical evidence of low serum testosterone should exist prior to the initiation of testosterone substitution.

Recommendation 6

1. Testosterone administration is absolutely contraindicated in men suspected of or having carcinoma of the prostate or breast.
   
2. Men with significant polycythemia, untreated sleep apnea, severe heart failure, severe symptoms of lower urinary tract obstruction evidenced by high scores in the International Prostate Symptom Score, or clinical findings of bladder outflow obstruction (increased post-micturition residual volume, decreased peak urinary flow, pathological pressure flow-studies) due to an enlarged, clinically benign prostate should not be treated with testosterone. Moderate obstruction represents a partial contraindication. After successful treatment of the obstruction, the contraindication is lifted.
   
3. In the absence of definite contraindications, age, as such, is not a contraindication to initiate testosterone substitution.
   

Recommendation 7

1. Preparations of natural testosterone should be used for substitution therapy. Currently available intramuscular, subdermal, transdermal, oral, and buccal preparations of testosterone are safe and effective. The treating physician should have sufficient knowledge and adequate understanding of the pharmacokinetics as well as of the advantages and drawbacks of each preparation. The selection of the preparation should be a joint decision of the patient and the physician.
   
2. Since the possible development of a contraindicationduring treatment (especially prostate carcinoma) requires rapid discontinuation of testosterone substitution, short-acting (transdermal, oral, buccal) preparations are preferred over long-acting (intramuscular, subdermal) depot preparations in patients with LOH.
   
3. Inadequate data are available to determine the optimal serum testosterone level for efficacy and safety. For the present time, mid- to lower young adult male serum testosterone levels seem appropriate and should be the therapeutic goal. Supraphysiological levels must be avoided. Although it may appear desirable, no evidence exists for or against the need to maintain the physiological circadian rhythm of serum testosterone levels.
   

Recommendation 8

1. Alkylated androgen preparations such as 17-methyl testosterone are obsolete because of their potential liver toxicity and should no longer be prescribed.
   
2. There is not enough evidence to recommend a substitution with DHT in aging men, and there is no evidence to recommend other androgen preparations such as DHEA, DHEA-S, androstenediol, or androstenedione for treatment.
   
3. hCG stimulates testosterone production of Leydig cells, albeit at a lower rate in older than in younger men. Since insufficient information exists about the effects and side effects of hCG treatment in older men, this treatment cannot be recommended in LOH.
   

Recommendation 9

Improvement in signs and symptoms of testosterone deficiency should be sought and failure-to-benefit clinical manifestations should result in discontinuation of treatment. Further investigation for other causes is then mandatory.

Recommendation 10

Digital rectal examination (DRE) and determination of serum prostate-specific antigen (PSA) are mandatory in men over the age of 45 years as baseline measurements of prostate health prior to therapy with testosterone, at quarterly intervals for the first 12 months, and yearly thereafter. Transrectal ultrasound-guided biopsies of the prostate are indicated only if the DRE or the serum PSA levels are abnormal.

Recommendation 11

Testosterone normally results in improvements in mood and well-being. The development of negative behavioral patterns during treatment calls for dose modifications or discontinuation of therapy.

Recommendation 12

Polycythemia occasionally develops during testosterone treatment. Periodic hematological assessment is indicated (ie, before treatment, every 3 months for 1 year, and then annually). Dose adjustments may be necessary.

Recommendation 13

Bone density increases under testosterone substitution and fracture rates may be reduced. Therefore, assessment of bone density at 2-year intervals may be advisable (if available and affordable).

Recommendation 14

Some men with erectile dysfunction and low serum testosterone may not respond adequately under testosterone treatment alone. In these cases, addition of phosphodiesterase 5–inhibitors may be indicated. Similarly, men with erectile dysfunction not responding to phosphodiesterase 5–inhibitors may have low serum testosterone and require testosterone substitution.

Recommendation 15

Men successfully treated for prostate cancer and suffering from confirmed symptomatic hypogonadism are candidates for testosterone substitution after a prudent interval if there is no evidence of residual cancer. The risk and benefits must be clearly understood by the patient and the follow-up must be particularly careful. No reliable evidence exists in favor of, or against, this recommendation. The clinicians must exercise good clinical judgment together with adequate knowledge of the advantages and drawbacks of testosterone therapy in this situation.

This article has been cited by other articles:

				T. H. Jones, S. Arver, H. M. Behre, J. Buvat, E. Meuleman, I. Moncada, A. M. Morales, M. Volterrani, A. Yellowlees, J. D. Howell, et al. Testosterone Replacement in Hypogonadal Men With Type 2 Diabetes and/or Metabolic Syndrome (the TIMES2 Study) Diabetes Care, April 1, 2011; 34(4): 828 - 837. [Abstract] [Full Text] [PDF]

				G. Kolovou, H. Bilianou, A. Marvaki, and D. P. Mikhailidis Aging Men and Lipids American Journal of Men's Health, March 1, 2011; 5(2): 152 - 165. [Abstract] [PDF]

				A. Tajar, G. Forti, T. W. O'Neill, D. M. Lee, A. J. Silman, J. D. Finn, G. Bartfai, S. Boonen, F. F. Casanueva, A. Giwercman, et al. Characteristics of Secondary, Primary, and Compensated Hypogonadism in Aging Men: Evidence from the European Male Ageing Study J. Clin. Endocrinol. Metab., April 1, 2010; 95(4): 1810 - 1818. [Abstract] [Full Text] [PDF]

				A. Theodoraki and P.-M. Bouloux Testosterone therapy in men Menopause Int, June 1, 2009; 15(2): 87 - 92. [Abstract] [Full Text] [PDF]

				C. Wang, E. Nieschlag, R. Swerdloff, H. M. Behre, W. J. Hellstrom, L. J. Gooren, J. M. Kaufman, J.-J. Legros, B. Lunenfeld, A. Morales, et al. Investigation, Treatment, and Monitoring of Late-Onset Hypogonadism in Males: ISA, ISSAM, EAU, EAA, and ASA Recommendations J Androl, January 1, 2009; 30(1): 1 - 9. [Full Text] [PDF]

				J. Reynard, S. Brewster, and S. Biers Late-onset hypogonadism (LOH) Oxford Handbook of Urology, January 1, 2009; 2(1): med-9780199534944-div1-23 - med-9780199534944-div1-23. [Full Text]

				J. Reynard, S. Brewster, and S. Biers Chapter 13 Sexual Health Oxford Handbook of Urology, January 1, 2009; 2(1): med-9780199534944-chapter - med-9780199534944-chapter. [Full Text]

				C Wang, E Nieschlag, R Swerdloff, H M Behre, W J Hellstrom, L J Gooren, J M Kaufman, J-J Legros, B Lunenfeld, A Morales, et al. Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations Eur. J. Endocrinol., November 1, 2008; 159(5): 507 - 514. [Full Text] [PDF]

				S. Loves, J. Ruinemans-Koerts, and H. de Boer Letrozole once a week normalizes serum testosterone in obesity-related male hypogonadism Eur. J. Endocrinol., May 1, 2008; 158(5): 741 - 747. [Abstract] [Full Text] [PDF]

				M. H. Emmelot-Vonk, H. J. J. Verhaar, H. R. Nakhai Pour, A. Aleman, T. M. T. W. Lock, J. L. H. R. Bosch, D. E. Grobbee, and Y. T. van der Schouw Effect of Testosterone Supplementation on Functional Mobility, Cognition, and Other Parameters in Older Men: A Randomized Controlled Trial JAMA, January 2, 2008; 299(1): 39 - 52. [Abstract] [Full Text] [PDF]

				T. H. Jones Chapter 3 Diagnosis of hypogonadism: symptoms, signs, tests, and guidelines OEL Testosterone Deficiency in Men, January 1, 2008; 1(1): med-9780199545131-chapter - med-9780199545131-chapter. [Abstract] [Full Text]

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nieschlag, E. Articles by Wu, F. C. W. Search for Related Content PubMed PubMed Citation Articles by Nieschlag, E. Articles by Wu, F. C. W.